Compare iShares Core MSCI EAFE ETF (IEFA) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI EAFE ETF vs Revvity Inc — how do they compare? iShares Core MSCI EAFE ETF trades at $101.02, while Revvity Inc trades at $117.6 (market cap $12.91B). The key difference: Revvity Inc pays a 0.24% dividend while iShares Core MSCI EAFE ETF pays none. Which is the better fit depends on your goals.
| IEFA | RVTY | |
|---|---|---|
Sector | Broad Market / Factor | Technology |
52-Week High | $101.09 | $117.75 |
52-Week Low | $84.72 | $82.26 |
Market Cap | — | $12.91B |
Enterprise Value | — | $15.23B |
Dividend Yield | — | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEFA trades at $100.895, up 0.36% today, with a bullish technical signal from moving averages and strong trend momentum indicated by ADX. The fund focuses on developed international markets excluding the U.S. and Canada, offering diversification benefits and a dividend yield of 3.30% as noted by The Motley Fool on June 13, 2026. Recent news highlights its cost efficiency compared to peers like EFA, with an expense ratio of 0.07%.
Outlook is positive due to defensive inflows and Fed cut potential, but risks include capped upside from covered call strategies and concentration in non-U.S. markets. Analyst sentiment is mixed, with some favoring broader ETFs like VXUS for higher returns.
RVTY trades at $116.10, up 0.07% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.41, surpassing the $1.21 estimate, and raised its full-year outlook due to robust diagnostics demand. Revenue remains steady around $2.9 billion, with a net income margin of 8.16%. Analyst consensus is a Buy with a $120.50 price target, and recent news highlights product launches like the SuperFlex prenatal system and high-throughput TB testing platform.
The outlook for RVTY is positive, supported by earnings momentum and strategic innovations, but investors face risks from high valuation multiples and competitive pressures in the healthcare sector. The stock's proximity to its consensus target suggests limited near-term upside, requiring careful monitoring of execution against raised guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Core MSCI EAFE ETF
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
